Lu-177 PSMA Therapy: Dosimetry & Safety

Lu-177 PSMA-617 (Pluvicto) is a targeted beta-particle therapy for PSMA-positive metastatic castration-resistant prostate cancer, and its safe delivery rests on two coupled pillars: MIRD-based organ dosimetry and an outpatient radiation-safety workflow. Because lutetium-177 pairs a therapeutic beta particle with imageable low-energy gamma rays, the same administered activity that treats the tumor can be imaged to quantify absorbed dose — making Lu-177 PSMA a genuine theranostic in which physics, not just pharmacology, defines the program. ¹⁴⁵

The dose-limiting organs are the kidneys and salivary glands, not the tumor, and the external hazard is modest enough that most patients go home the same day. That combination — internal dose management plus a defensible patient-release calculation — is what a medical physicist and radiation safety officer build the program around. ⁵⁸

Introduction

Prostate-specific membrane antigen (PSMA) is a transmembrane protein highly expressed on most prostate-cancer cells. Lu-177 PSMA-617 exploits that target by conjugating the PSMA-binding ligand PSMA-617 to lutetium-177, a beta-emitting radionuclide. Administered intravenously, the radioligand concentrates in PSMA-expressing tumor and delivers a cytotoxic beta dose over a short range in tissue while largely sparing distant normal organs. ¹⁴

The pivotal VISION trial randomized 831 patients with PSMA-positive metastatic castration-resistant prostate cancer who had progressed after androgen-receptor-pathway inhibition and taxane chemotherapy. Adding Lu-177 PSMA-617 to standard care significantly prolonged both imaging-based progression-free survival (median 8.7 vs 3.4 months) and overall survival (median 15.3 vs 11.3 months; hazard ratio for death 0.62), with a manageable safety profile. ¹ On the strength of these data, the FDA approved Pluvicto in 2022, and in 2025 expanded the indication to an earlier line of therapy. ²³

This guide covers the physics of Lu-177 as a theranostic radionuclide, the MIRD dosimetry framework and the organ doses that bound therapy, the outpatient radiation-safety workflow, the practical controls a program needs, and the NRC medical-use regulations that govern it.

Topic Explanation

What is Lu-177 PSMA-617 therapy?

Lu-177 PSMA-617 therapy is a radioligand therapy (RLT) in which a PSMA-targeting small molecule delivers lutetium-177 to prostate-cancer cells, where its beta emission deposits therapeutic radiation dose. The approved regimen is 7.4 GBq (200 mCi) administered intravenously every six weeks for up to six doses, or until disease progression or unacceptable toxicity. ²

Key terms used throughout this guide:

Radioligand therapy (RLT) — systemic therapy delivering a radionuclide to tumor via a targeting molecule.
Theranostic — a radionuclide or agent that supports both imaging (diagnosis, dosimetry) and therapy.
Time-integrated activity — the total number of decays occurring in a source region, obtained by integrating the activity–time curve.
S-value — the mean absorbed dose to a target organ per unit time-integrated activity in a source organ, for a specific radionuclide and anatomic model.
Patient release — the regulatory determination that a treated patient may leave the facility without exceeding public-dose limits to others.

Why Lu-177 is a theranostic radionuclide

Lutetium-177 decays to stable hafnium-177 with a physical half-life of about 6.647 days. Its principal emission is a beta particle with a maximum energy of approximately 497 keV, which delivers therapeutic dose over a soft-tissue range of only a few millimeters — ideal for irradiating tumor while sparing tissue a short distance away. Critically, Lu-177 also emits low-abundance gamma rays at 113 keV (about 6%) and 208 keV (about 10–11%), which fall in the imageable range of a SPECT/CT gamma camera. ¹⁰

This dual character is the whole point: the low-energy, low-abundance gammas are weak enough to keep the external radiation hazard modest, yet present enough to allow post-therapy SPECT/CT imaging and quantitative dosimetry from the very dose that treats the patient. That is why Lu-177 PSMA pairs naturally with Ga-68 PSMA PET imaging for patient selection — the two form a theranostic pair. For the imaging side of that pair, see our guide to Ga-68 PSMA PET imaging, and for the broader dosimetry framework, Lu-177 theranostics dosimetry.

Key Technical Principles

The MIRD dose equation

Internal organ dosimetry follows the Medical Internal Radiation Dose (MIRD) schema. The mean absorbed dose $\overset{ˉ}{D} (r_{T})$ to a target region $r_{T}$ is the sum over source regions $r_{S}$ of the time-integrated activity $\tilde{A} (r_{S})$ multiplied by the radionuclide-specific S-value: ⁵

\overset{ˉ}{D} (r_{T}) = r_{S} \sum \tilde{A} (r_{S}) S (r_{T} \leftarrow r_{S})

The time-integrated activity is obtained by integrating the measured activity–time curve in each source region:

\tilde{A} (r_{S}) = \int_{0}^{\infty} A (r_{S}, t) d t

In practice, $A (r_{S}, t)$ is sampled by serial quantitative SPECT/CT at several time points (for example, roughly 24, 48, 96, and 168 hours after administration), and the curve is fit and integrated to capture both uptake and clearance. ⁵ The physics of quantitative SPECT calibration that underlies this is covered in our guide to quantitative SPECT/CT calibration.

Organ absorbed-dose coefficients

Published Lu-177 PSMA-617 dosimetry shows that tumor receives several times the dose delivered to critical organs, and that the kidneys and salivary glands — not the tumor — set the practical limits. Representative absorbed-dose coefficients from an early dosimetry series are summarized below. ⁵

Region	Representative absorbed dose per unit activity	Role in therapy
Tumor lesion	~6.1 Gy/GBq	Therapeutic target; 6–12× the dose to critical organs ⁵
Kidney (each)	~0.5–0.6 Gy/GBq	Dose-limiting; renal clearance of ligand ⁵
Salivary glands	~1.0 Gy/GBq	Dose-limiting for xerostomia; physiologic uptake ⁵
Red marrow	Lower per-GBq, but drives myelosuppression	Hematologic toxicity monitoring ¹⁴

Worked kidney-dose example

For a single 7.4 GBq administration, taking a kidney coefficient of 0.6 Gy/GBq, the estimated absorbed dose to each kidney per cycle is:

D_{kidney} = 0.6 \frac{Gy}{GBq} \times 7.4 GBq \approx 4.4 Gy per cycle

Across a full six-cycle course, the simple cumulative sum approaches the range of published renal-tolerance concerns, which is why the kidneys are tracked cycle-by-cycle; in one dosimetry series the total dose per kidney did not exceed 23 Gy in any patient. ⁵ Because cumulative renal dose — accounting for repair between cycles — is the constraint, patient-specific dosimetry, not a fixed activity alone, is the physically defensible way to manage a full course. ⁴⁵

External dose rate and the patient as a source

After administration, the treated patient becomes a distributed Lu-177 source. Because only low-energy, low-abundance gammas escape the body, the external dose-rate constant for Lu-177 is small — on the order of 0.007–0.008 µSv·m²·MBq⁻¹·h⁻¹ in compiled radionuclide data. ⁶ The unshielded dose rate at distance $d$ from a point-source approximation of retained activity $A$ is:

\dot{D} = \frac{Γ \cdot A}{d ^{2}}

This low constant is why external exposure to staff and the public is modest and why most Lu-177 PSMA patients qualify for same-day release — the dominant residual radiation-safety concern is contamination from renally excreted activity, not external dose. ⁶⁸

Clinical Impact

Lu-177 PSMA-617 changed the treatment landscape for advanced prostate cancer, and it brings radioligand therapy into community and hospital nuclear-medicine practices that must now support therapy-grade dosimetry and radiation safety. The VISION survival benefit, and the 2025 expansion of the indication to an earlier line, mean more facilities are standing up PSMA-RLT programs — and each one needs the physics and safety infrastructure to run it defensibly. ¹³

Clinically, the dose-limiting organs translate into the characteristic toxicities: dry mouth (xerostomia) from salivary uptake, renal-function monitoring from kidney clearance, and myelosuppression from marrow dose. ¹⁴ A dosimetry-informed program can identify patients whose kidney or marrow dose is trending toward tolerance and individualize subsequent cycles, rather than treating every patient with an identical fixed activity regardless of biodistribution. Pretherapy Ga-68 PSMA PET uptake correlates with subsequent Lu-177 PSMA organ and tumor dose, supporting patient selection and rough dose prediction before the first therapeutic administration. ¹¹

The theranostic pairing also distinguishes Lu-177 PSMA (Pluvicto, for prostate cancer) from Lu-177 DOTATATE (Lutathera, for neuroendocrine tumors): both use the same radionuclide and MIRD framework, but their targeting molecules, biodistribution, and dose-limiting considerations differ, so a facility running both cannot simply copy one program's procedures onto the other. For the neuroendocrine counterpart, see our guide to Lu-177 DOTATATE PRRT.

Practical Optimization Tips

Build the program around quantitative SPECT/CT

Post-therapy SPECT/CT imaging is the engine of Lu-177 PSMA dosimetry. Calibrate the camera for quantitative Lu-177 imaging, standardize acquisition time points, and use a consistent reconstruction with attenuation and scatter correction so that time–activity curves are comparable across cycles and patients. ⁵ Without a calibrated quantitative workflow, "dosimetry" reduces to guesswork.

Track the kidneys and marrow cycle by cycle

Because cumulative renal dose is the binding constraint, record per-cycle kidney absorbed dose and trend it against renal-tolerance guidance, adjusting activity or interval where a dosimetry-based program permits. Monitor blood counts for marrow toxicity between cycles. ⁴⁵

Control contamination from excreted activity

PSMA ligands are cleared renally, so urine is the dominant contamination pathway. Provide dedicated or well-managed toilet facilities, absorbent-pad protocols, glove and surface controls, and clear patient hygiene instructions. Survey administration and restroom areas after treatment. Our guide to nuclear medicine decontamination best practices covers the survey-and-cleanup workflow.

Perform a patient-specific release calculation

Do not rely on a generic assumption that "Lu-177 is always releasable." Perform the 10 CFR 35.75 calculation using the administered activity, physical and biological clearance, and realistic occupancy assumptions for the people the patient will contact, and issue written instructions. Document the basis so the release is defensible on inspection. ⁸ Our guide to patient release after radiopharmaceutical therapy walks through the calculation.

Coordinate licensing before the first dose

A PSMA-RLT program requires the therapy on the materials license, an authorized user, an authorized medical physicist where required, written directives, and procedures — all in place before treating. Coordinate the amendment early, since license changes take time. ⁷⁹

Regulatory Considerations

Lu-177 is byproduct material, so its medical use is governed by the NRC under 10 CFR Part 35, or by the equivalent Agreement State program, with dose limits set by 10 CFR Part 20. A PSMA-RLT program sits squarely in the "written-directive" category of medical use, with corresponding requirements for authorized users, dosimetry, and recordkeeping. ⁷⁹

Key frameworks to reference:

10 CFR Part 20 — Standards for Protection Against Radiation, setting occupational and public dose limits that bound staff exposure and patient-release decisions. ⁹
10 CFR Part 35 — Medical Use of Byproduct Material, governing authorized users, written directives, dose measurement, and the radiation safety officer's responsibilities for therapy radionuclides, including patient release under 10 CFR 35.75. ⁷
NRC Regulatory Guide 8.39 — Release of Patients Administered Radioactive Material, providing the accepted methodology and the 5 mSv (0.5 rem) constraint on total effective dose to any other individual from the released patient. ⁸
NRC NUREG-1556, Volume 9 — program-specific licensing guidance for medical-use licenses, including expectations for therapy procedures and facility controls. ⁷
FDA prescribing information and EANM procedure guidelines — the Pluvicto label defines the approved activity and schedule, and the EANM PSMA-RLT guideline provides best-practice guidance on patient selection, administration, dosimetry, and follow-up. ²⁴

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license before relying on any release or dosimetry assumption. For the shielding side of a therapy program, see our guide to RPT shielding for Lu-177, Ra-223, and Ac-225.

Frequently Asked Questions (FAQs)

What is Lu-177 PSMA-617 (Pluvicto) therapy?

Lu-177 PSMA-617, marketed as Pluvicto, is a radioligand therapy for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. It links lutetium-177, a beta-emitting radionuclide, to a small molecule that binds PSMA on prostate-cancer cells, delivering targeted beta radiation to tumor while sparing most normal tissue. The FDA-approved regimen is 7.4 GBq (200 mCi) intravenously every 6 weeks for up to six doses.

Which organs limit the dose in Lu-177 PSMA therapy?

The kidneys and salivary glands are the principal dose-limiting organs because PSMA ligands are cleared renally and also accumulate in salivary and lacrimal tissue. Published dosimetry reports absorbed doses on the order of 0.5 to 0.6 Gy per GBq to each kidney and about 1.0 Gy per GBq to the salivary glands, versus roughly 6 Gy per GBq to tumor. Bone marrow dose also matters because it drives myelosuppression.

Can Lu-177 PSMA patients be treated as outpatients?

Yes, in most cases. Lutetium-177 emits only low-energy, low-abundance gamma rays alongside its therapeutic beta particle, so external dose rates from the patient are low. Patients are typically released under NRC 10 CFR 35.75 and Regulatory Guide 8.39 after a patient-specific calculation confirms the total effective dose to any other individual will not exceed 5 mSv, together with written radiation-safety instructions.

Why is Lu-177 useful for both therapy and imaging?

Lutetium-177 is a theranostic radionuclide: its beta particle (maximum energy about 497 keV) delivers therapeutic dose over a short tissue range, while its low-abundance 113 keV and 208 keV gamma emissions can be imaged on a SPECT/CT gamma camera. That allows post-therapy imaging and quantitative dosimetry from the same administered dose that treats the patient.

How is organ dose calculated in Lu-177 PSMA therapy?

Organ dosimetry uses the MIRD schema, in which the mean absorbed dose to a target organ equals the time-integrated activity in the source regions multiplied by radionuclide- and geometry-specific S-values. Time-integrated activity is derived from serial quantitative SPECT/CT imaging at several time points after administration, which captures uptake and clearance in tumor and normal organs.

What radiation-safety controls does a Lu-177 PSMA program need?

A program needs an NRC or Agreement State materials license authorizing the therapy, an authorized user and authorized medical physicist, written directives, dose preparation and administration procedures, contamination control for urine and body fluids (PSMA ligands are renally excreted), patient-release calculations and instructions, waste management, and staff training. The medical physicist supports dosimetry, surveys, and release documentation.

Key Takeaways

Lu-177 PSMA-617 is a theranostic beta therapy. Its short-range beta treats tumor while its low-abundance 113 keV and 208 keV gammas allow post-therapy imaging and dosimetry. ¹⁰
The kidneys and salivary glands are dose-limiting. Representative doses are ~0.5–0.6 Gy/GBq per kidney and ~1.0 Gy/GBq to the salivary glands, against ~6 Gy/GBq to tumor. ⁵
Dosimetry follows the MIRD schema. Mean organ dose is time-integrated activity times S-value, with activity–time curves built from serial quantitative SPECT/CT. ⁵
Most patients are outpatients. Low external dose rates support same-day release under 10 CFR 35.75 and Reg Guide 8.39, with contamination — not external dose — the residual concern. ⁶⁸
Licensing and written directives come first. The therapy must be on the materials license with an authorized user and medical physicist before the first administration. ⁷

Conclusion

Lu-177 PSMA-617 is a milestone in prostate-cancer care and a defining example of the theranostic model, where the physics of a single radionuclide underpins both treatment and its verification. Running the therapy well means treating dosimetry and radiation safety as first-class parts of the program: calibrated quantitative SPECT/CT, cycle-by-cycle kidney and marrow tracking, contamination control for renally excreted activity, and a defensible patient-release calculation for each treatment. Facilities that build this physics and safety infrastructure — rather than treating Lu-177 PSMA as a simple injection — deliver the survival benefit demonstrated in VISION while protecting patients, staff, and the public. ¹⁵

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and radioligand-therapy programs stand up and sustain Lu-177 PSMA therapy. Our board-certified medical physicists support PET/CT and nuclear medicine physics, quantitative SPECT/CT calibration and dosimetry, patient-release calculations and instructions, contamination-survey and waste procedures, radioactive material license support, and radiation safety officer program guidance across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

A strong theranostics program makes dosimetry and radiation safety routine, defensible, and easy for the clinical team to execute cycle after cycle.

Related Resources

References

Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322. PubMed
U.S. Food and Drug Administration. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) injection — Prescribing Information. 2022. accessdata.fda.gov
U.S. Food and Drug Administration. FDA expands Pluvicto's metastatic castration-resistant prostate cancer indication. 2025. fda.gov
Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536-2544. doi:10.1007/s00259-019-04485-3. PubMed
Fendler WP, Reinhardt S, Ilhan H, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581-3590. doi:10.18632/oncotarget.12240. PubMed
Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Phys. 2012;102(3):271-291. doi:10.1097/HP.0b013e318235153a. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. nrc.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39, Revision 1: Release of Patients Administered Radioactive Material. 2020. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. nrc.gov
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Ann ICRP. 2008;38(3). icrp.org
Wang J, Zang J, Wang H, et al. Pretherapeutic 68Ga-PSMA-617 PET may indicate the dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in main organs and tumor lesions. Clin Nucl Med. 2019;44(6):431-438. doi:10.1097/RLU.0000000000002575. PubMed
Chandran E, Figg WD, Madan R. Lutetium-177-PSMA-617: a vision of the future. Cancer Biol Ther. 2022;23(1):186-190. doi:10.1080/15384047.2022.2037985. PubMed
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Program-Specific Guidance About Medical Use Licenses. nrc.gov